MindWalk Holdings (HYFT) Asset Utilization Ratio (2021 - 2026)
MindWalk Holdings (HYFT) posted quarterly Asset Utilization Ratio of 371.93 for Q2 2026, up 75.3% year-over-year from 212.17 in Q2 2025, and down 16.55% quarter-over-quarter from 445.67 in Q1 2026.
Powered by 
Analysis
MindWalk Holdings (HYFT) Asset Utilization Ratio (2021 - 2026) Analysis & Trends
MindWalk Holdings (HYFT) has reported Asset Utilization Ratio for 6 consecutive years, with 371.93 the latest figure, recorded in Q2 2026.
- In Q2 2026, Asset Utilization Ratio rose 75.3% year-over-year to 371.93; the TTM figure through Apr 2026 stood at 371.93 (up 75.3% YoY), while the FY2026 annual figure was 0.48, up 139.17% from the prior year.
- Asset Utilization Ratio declined to 371.93 in Q2 2026 per HYFT's latest filing, from 445.67 in the prior quarter.
- Across five years, Asset Utilization Ratio topped out at 445.67 in Q1 2026 and bottomed at 0.08 in Q1 2022.
- Historically, Asset Utilization Ratio has averaged 91.6 across 5 years, with a median of 0.3 in 2024.
- Annual changes were most pronounced in 2024 — Asset Utilization Ratio sank 42.91% — and 2025, when it soared 141764.74%.
- MindWalk Holdings' Asset Utilization Ratio stood at 0.25 in 2022, then advanced by 19.21% to 0.3 in 2023, then surged by 13864.07% to 41.43 in 2024, then soared by 684.99% to 325.25 in 2025, then rose by 14.35% to 371.93 in 2026.
- Business Quant data shows HYFT's Asset Utilization Ratio at 371.93 in Q2 2026, 445.67 in Q1 2026, and 325.25 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.62 Bn | 131.77 Bn | 2.84 Bn | 0.47 |
| 2 | Regeneron Pharmaceuticals | 85.73 Bn | 77.73 Bn | 3.93 Bn | 0.38 |
| 3 | Argenx Se | 63.53 Bn | 58.35 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.23 Bn | 53.09 Bn | 52.00 Mn | 0.20 |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | - |
| 6 | BeOne Medicines | 40.03 Bn | 34.93 Bn | 1.53 Bn | 0.69 |
| 7 | Alnylam Pharmaceuticals | 35.50 Bn | 32.19 Bn | 992.69 Mn | 0.90 |
| 8 | Royalty Pharma | 28.52 Bn | 27.68 Bn | - | 0.13 |
| 9 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | 0.54 |
| 10 | MindWalk Holdings | 60.76 Mn | 52.48 Mn | 1.82 Mn | 0.70 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Apr 30, 2026 | 0.70 |
| Jan 31, 2026 | 0.74 |
| Oct 31, 2025 | 0.50 |
| Jul 31, 2025 | 0.36 |
| Apr 30, 2025 | 57.34 |
| Jan 31, 2025 | 47.49 |
| Oct 31, 2024 | 41.43 |
| Jul 31, 2024 | 41.34 |
| Apr 30, 2024 | 0.15 |
| Jan 31, 2024 | 0.31 |
| Oct 31, 2023 | 0.30 |
| Jul 31, 2023 | 0.28 |
| Apr 30, 2023 | 0.26 |
| Jan 31, 2023 | 0.25 |
| Oct 31, 2022 | 0.25 |
| Jul 31, 2022 | 0.23 |
| Apr 30, 2022 | 0.26 |
| Jan 31, 2022 | 0.33 |
| Oct 31, 2021 | 0.30 |
| Jul 31, 2021 | 0.28 |